Similar articles

• [Predictive testing for p53-mutations; ethical considerations. National Work Group Hereditary Mamma Carcinoma].

  de Wert GM. de Wert GM. Ned Tijdschr Geneeskd. 1996 Jun 29;140(26):1350-3. Ned Tijdschr Geneeskd. 1996. PMID: 8710023 Dutch. No abstract available.
• Germline TP53 alterations in Finnish breast cancer families are rare and occur at conserved mutation-prone sites.

  Rapakko K, Allinen M, Syrjäkoski K, Vahteristo P, Huusko P, Vähäkangas K, Eerola H, Kainu T, Kallioniemi OP, Nevanlinna H, Winqvist R. Rapakko K, et al. Br J Cancer. 2001 Jan 5;84(1):116-9. doi: 10.1054/bjoc.2000.1530. Br J Cancer. 2001. PMID: 11139324 Free PMC article.
• Li-Fraumeni and related syndromes: correlation between tumor type, family structure, and TP53 genotype.

  Olivier M, Goldgar DE, Sodha N, Ohgaki H, Kleihues P, Hainaut P, Eeles RA. Olivier M, et al. Cancer Res. 2003 Oct 15;63(20):6643-50. Cancer Res. 2003. PMID: 14583457
• [Li-Fraumeni syndrome and germ-line mutations of the p53 gene].

  Leblanc T, Soussi T. Leblanc T, et al. Arch Pediatr. 1994 Jan;1(1):61-70. Arch Pediatr. 1994. PMID: 8087224 Review. French.
• [Li-Fraumeni syndrome].

  Frebourg T. Frebourg T. Bull Cancer. 1997 Jul;84(7):735-40. Bull Cancer. 1997. PMID: 9339200 Review. French.